1 / 6

GLP Peptides · Popular Peptides

GLP3-RT (Trinity-X)

$104.00

99% Pure | Multi Dose | Finished in the USA

GLP3-RT (Trinity-X™) is a cutting-edge tri-agonist peptide that is transforming the field of metabolic research. Engineered to simultaneously activate three key metabolic receptors—GLP-1, GIP, and GCGR (glucagon)—this multifunctional compound offers a comprehensive and synergistic approach to modulating appetite signaling, enhancing insulin function, and accelerating fat metabolism pathways in research settings.

Select dose

Build a Pack & Save Up to 20%

Ships in 24 hrs

Free standard shipping on orders $250+Free standard shipping $250+

Lab report included

GLP3-RT (Trinity-X) · 10mg

$104.00

Recommended with this order

Frequently paired with this compound by other researchers.

Bacteriostatic Reconstitution Water (BAC)$8.00

10ml

For Research Use Only. Not for human consumption or therapeutic treatment.

AboutLab reportSpecificationsQuestions

99% Pure | Multi Dose | Finished in the USA

GLP3-RT (Trinity-X™) is a cutting-edge tri-agonist peptide that is transforming the field of metabolic research. Engineered to simultaneously activate three key metabolic receptors—GLP-1, GIP, and GCGR (glucagon)—this multifunctional compound offers a comprehensive and synergistic approach to modulating appetite signaling, enhancing insulin function, and accelerating fat metabolism pathways in research settings.

What Is Trinity-X?

Trinity-X™ is a 39-amino-acid synthetic peptide engineered as a tri-agonist for the GLP-1, GIP, and glucagon receptors. By combining three receptor activities into a single stable compound, Trinity-X provides a powerful research tool to investigate multi-pathway metabolic control, including satiety signaling, insulin secretion dynamics, and lipid breakdown mechanisms—without requiring separate agonists for each pathway.

Why Choose Trinity-X?

Researchers choose Trinity-X when they need a single-molecule solution for complex metabolic-health studies. Its tri-agonist design delivers synchronized receptor activation that enables streamlined protocols for:

What Sets Trinity-X Apart?

Unlike single-pathway peptides or even dual-agonists, Trinity-X uniquely merges GLP-1, GIP, and glucagon receptor activities into one stable compound. This integrated tri-agonist approach produces synergistic metabolic effects that cannot be achieved with other research peptides:

Research observations

Observed Mass Modulation in Research Models

In controlled laboratory studies, models administered Trinity-X exhibited significant reductions in baseline mass over extended evaluation periods. Phase-2 research data suggests substantial metabolic effects when all three receptor pathways are engaged simultaneously. For research use only. Not for human or veterinary use.

Blood Sugar and Insulin Markers in Research

In controlled laboratory studies, Trinity-X has been observed to influence key biomarkers including HbA1c levels, fasting glucose concentrations, and insulin sensitivity in experimental models. These findings suggest significant metabolic modulation potential for further investigation. For research use only. Not for human consumption or therapeutic application.

Cardiometabolic Biomarker Research Potential

In controlled research settings, studies on Trinity-X have observed improvements in systolic and diastolic blood pressure readings, enhanced lipid profiles including LDL markers, and changes in visceral adiposity measurements in animal models. These findings support further exploration in cardiometabolic-focused peptide research. This product is for laboratory research use only. Not for human or therapeutic use.

Weekly Micro-Dosing Efficiency in Research Protocols

Research trials often employ a once-weekly subcutaneous micro-dosing approach, typically around 0.1 mL, to maintain consistent exposure levels in peptide models. This allows for sustained analysis without requiring daily administration, making Trinity-X ideal for longitudinal research protocols. For research use only. Not approved for human consumption or clinical use.

Tolerability Profile in Research Models

Research models receiving Trinity-X have shown mild and temporary gastrointestinal responses, generally decreasing as concentration protocols are stabilized. These observations are consistent with incretin-related pathway activation patterns commonly seen in tri-agonist research. Trinity-X is not intended for human or diagnostic use. For qualified research personnel only.

10mg

Tested 12-Aug-2026

Kovera · 3 reports

2 earlier

20mg

Tested 12-Aug-2026

Kovera · 2 reports

1 earlier

CompoundGLP3-RT (Trinity-X)

Research areaGLP Peptides, Popular Peptides, Hollywood Stack, Metabolic Peptides, Mitochondrial & Metabolic Pathway Research

FormatLyophilised powder, sealed glass vial

Sizes10mg · 12mg · 20mg

Reconstituted shelf life30 days at 2–8°C

Independent laboratoryFreedom Diagnostics and Kovera

Lab reports on file5 reports

Ships fromSaint Petersburg, FL and California

DispatchWithin 24 hours

Trinity-X is a research-grade peptide known for its tri-agonist activity— activating GLP-1, GIP, and glucagon receptors simultaneously. It is being studied in scientific settings for its unique mechanism of action across multiple metabolic pathways.

The name “Trinity-X” refers to its triple-receptor mechanism—three pathways activated by one molecule. The “X” represents the cutting-edge, nextgeneration nature of this research compound.

No. Trinity-X is a synthetic peptide, engineered in laboratory settings to mimic and enhance the function of naturally occurring hormonal pathways in research models.

Trinity-X is commonly studied in metabolic, obesity, glucose regulation, and energy balance models. Its triple-receptor profile makes it an ideal candidate for preclinical exploration of multi-receptor metabolic interactions.

Research protocols often begin with 0.25mg and may scale to 0.5mg or 1mg, depending on the experimental model and study goals. Concentration should be determined based on internal SOPs and protocol requirements.

Yes. Concentration charts for Trinity-X are typically created based on model weight, study length, and receptor activation goals. Charts often show titration schedules from 0.25mg up to 1mg over several weeks.

Trinity-X is available in 10mg, 12mg, 20mg, and 24mg vial sizes, allowing researchers to select the optimal quantity for their specific protocols.

Yes. Trinity-X is frequently used in research stacks with peptides such as Tesamorelin, MOTS-c, 5-Amino-1MQ, or Cagrilintide to explore synergistic effects in metabolic modeling.

Trinity-X activates three receptors simultaneously (GLP-1, GIP, glucagon), while single-receptor peptides only target one pathway. This tri-agonist approach produces synergistic metabolic effects not achievable with monoagonists.

Lyophilized Trinity-X should be stored at or below -20°C for long-term stability. After reconstitution, storage in a refrigerated environment (2-8°C) is recommended, with use within 7-14 days per research protocol.